Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
3.
Arch Dermatol Res ; 316(1): 47, 2023 Dec 16.
Artículo en Inglés | MEDLINE | ID: mdl-38103110

RESUMEN

Post-surgical scarring impacts quality of life (QOL) and is a significant source of morbidity. Existing treatments targeted at improving the appearance and morbidity of scarring include laser-based therapies. Although lasers are frequently used to improve scar appearance, the effects on QOL are unclear. A scoping review was conducted to assess the impact of laser-based therapy for patients with surgical facial scarring on QOL. Throughout literature review was conducted with the guidance of a medical librarian. Relevant articles underwent two rounds of screening by two, independent reviewers. Data were extracted from each article and later analyzed. Of the four articles analyzed, laser-based therapies were demonstrated as effective in improving QOL for patients with facial scars resultant from surgical intervention. Laser-based therapy should be considered when treating facial scarring resultant from surgical intervention, as it has been shown to improve patient QOL. Standardization of QOL assessment and further studies expanding scar inclusion should be pursued given the paucity of information found through this review.


Asunto(s)
Terapia por Láser , Terapia por Luz de Baja Intensidad , Humanos , Cicatriz/etiología , Cicatriz/cirugía , Calidad de Vida , Terapia por Láser/efectos adversos , Rayos Láser , Resultado del Tratamiento
4.
Fam Cancer ; 22(3): 295-301, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-36437392

RESUMEN

Immunohistochemistry (IHC) of cutaneous sebaceous lesions (SL) can be used to screen patients for Lynch syndrome (LS). There is little data on rates of genetic referral and outcomes of genetic testing for patients with SL. This single-center retrospective study characterizes 400 + patients with SL, including IHC results, genetics referrals, and outcomes of genetic testing. Retrospective chart reviews were performed for patients with a pathology-confirmed diagnosis of SL at the University of Michigan between January 2009 and December 2019. 447 patients with 473 SL were identified. Excluding 20 patients with known LS, IHC was conducted in 173 (41%) patients. 92/173 (53%) patients had abnormal results. 69 of these 92 (75%) patients were referred to genetics. 32 additional patients were referred with normal IHC (n = 22) or without IHC (n = 10). Of 101 patients referred, 65 (64%) were seen and 47 (47%) completed genetic testing. 7/47 (15%) had pathogenic variants associated with LS, six with concordant abnormal IHC and one without IHC. Cancer genetics referral of patients with SL, particularly for lesions with abnormal IHC, yields a significant rate of LS diagnosis. Providers should consider genetics referral for patients with SL.


Asunto(s)
Neoplasias Colorrectales Hereditarias sin Poliposis , Humanos , Estudios Retrospectivos , Neoplasias Colorrectales Hereditarias sin Poliposis/diagnóstico , Neoplasias Colorrectales Hereditarias sin Poliposis/genética , Mutación de Línea Germinal , Pruebas Genéticas/métodos , Derivación y Consulta , Reparación de la Incompatibilidad de ADN
5.
Pediatr Dermatol ; 40(1): 142-143, 2023 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-36039501

RESUMEN

Congenital skin pits have been observed as a sporadic anatomic variant as well as in association with trauma, maternal infection, genetic syndromes, and metabolic disorders. We present a case of a neonate with paired unilateral scapular pits, which to our knowledge has not yet been reported. Although this is favored to be a benign finding in an otherwise healthy baby, we review important considerations in the clinical evaluation of a neonate with congenital skin pitting.


Asunto(s)
Escápula , Anomalías Cutáneas , Lactante , Recién Nacido , Humanos , Piel
6.
Hepatol Commun ; 5(11): 1888-1900, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34558806

RESUMEN

Nucleoside analogue (NA) therapy for chronic hepatitis B (CHB) is associated with improved clinical outcomes, but usually requires long-term use. Whether treatment can be safely withdrawn and the factors associated with post-withdrawal outcome are not well defined. To assess long-term outcomes after stopping antiviral therapy, patients with hepatitis B e antigen (HBeAg)-negative CHB who had received antiviral therapy for 4 or more years with hepatitis B virus (HBV) DNA (≤100 IU/mL) were prospectively withdrawn from antiviral therapy and monitored monthly for the initial 6 months and every 3 months thereafter. Those with clinical relapse were retreated according to severity of relapse. Fifteen patients were withdrawn from lamivudine (4), adefovir (5), or a combination of the two (6) after a mean treatment duration of 8.4 years. The mean age was 45 years, 13 were male, and 8 were initially HBeAg-positive before treatment. After a mean follow-up of 6.6 years, outcomes differed by pretreatment HBeAg status. All patients who were HBeAg+ before treatment experienced virological relapse (8 of 8); 6 of 8 experienced clinical relapse; 4 of 8 had ALT flares; 5 of 8 required re-initiation of treatment, one of whom cleared hepatitis B surface antigen (HBsAg); and 3 of 8 remained off treatment, one of whom cleared HBsAg. In contrast, 4 of 7 patients who were HBeAg-negative before treatment experienced virological relapse, 3 of 7 experienced clinical relapse, and 1 of 7 had an alanine aminotransferase (ALT) flare. None restarted treatment, and 4 of 7 cleared HBsAg. Low pre-withdrawal HBsAg level was predictive of HBsAg loss. Conclusion: NA therapy can be safely withdrawn with long-term remission and high rates of HBsAg loss in most HBeAg-negative patients without cirrhosis. Patients who were initially HBeAg+ should not be withdrawn from treatment, because clinical relapse was frequent and often severe.


Asunto(s)
Antivirales/administración & dosificación , Hepatitis B Crónica/tratamiento farmacológico , Privación de Tratamiento , Adulto , ADN Viral/sangre , Femenino , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos de Superficie de la Hepatitis B/inmunología , Virus de la Hepatitis B/efectos de los fármacos , Hepatitis B Crónica/sangre , Humanos , Quimioterapia de Inducción , Masculino , Persona de Mediana Edad , Proyectos Piloto , Estudios Prospectivos , Recurrencia , Respuesta Virológica Sostenida
7.
J Surg Res ; 264: 8-15, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-33744776

RESUMEN

BACKGROUND: At the patient level, optimizing risk factors before surgery is a proven approach to improve patient outcomes after hernia repair. However, nearly 25% of patients are not adequately optimized before surgery. It is currently unknown how surgeon-level adherence to preoperative optimization impacts postoperative outcomes. In this context, we evaluated the association between surgeon adherence to optimization practices and surgeon-level postoperative outcomes. MATERIALS AND METHODS: Michigan Surgical Quality Collaborative data from 2014 to 2018 was analyzed to examine rates of surgeon adherence to preoperative optimization when performing elective ventral and incisional hernia repair. Adherence was defined as operating on patients who were nontobacco users with a body mass index >18.5 kg/m2 and <40 kg/m2. Surgeons were assigned a risk- and reliability-adjusted adherence rate which was used to divide surgeons into tertiles. Outcomes were compared between adherence tertiles. RESULTS: Across 70 hospitals in Michigan, 15,016 patients underwent ventral and incisional hernia repair, cared for by 454 surgeons. Surgeon adherence to preoperative optimization ranged from 51% to 76%. Surgeons in the lowest optimization tertile had higher rates of emergency department visits (8.78% versus 7.05% versus 7.03%, P < 0.001), serious complications (2.12% versus 1.56% versus 1.84%, P = 0.041), and any complication (4.08% versus 3.37% versus 4.04%, P = 0.043), than middle and high optimization tertiles. CONCLUSIONS: Surgeons' clinical outcomes, including complication rates, are affected by the proportion of their patients who are preoperatively optimized with regard to obesity and tobacco use. These results suggest that surgeons can improve their postoperative outcomes by addressing these issues before surgery.


Asunto(s)
Adhesión a Directriz/estadística & datos numéricos , Herniorrafia/efectos adversos , Complicaciones Posoperatorias/epidemiología , Cuidados Preoperatorios/normas , Cirujanos/estadística & datos numéricos , Adulto , Anciano , Procedimientos Quirúrgicos Electivos/efectos adversos , Femenino , Hernia Ventral/cirugía , Humanos , Hernia Incisional/cirugía , Masculino , Persona de Mediana Edad , Obesidad/epidemiología , Obesidad/terapia , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/prevención & control , Guías de Práctica Clínica como Asunto , Cuidados Preoperatorios/estadística & datos numéricos , Reproducibilidad de los Resultados , Estudios Retrospectivos , Factores de Riesgo , Cese del Hábito de Fumar , Cirujanos/normas , Fumar Tabaco/epidemiología , Fumar Tabaco/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...